Portola Pharmaceuticals

Therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.

Launch date

2003

Employees

Market cap

Enterprise valuation

€1.3b (Public information from May 2020)

San Francisco California (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018	2019
R&D budget	184m	234m	168m	188m	111m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Alta Partners Advanced Technology Ventures Frazier Healthcare Partners Sutter Hill Ventures MPM BioImpact Prospect Venture Partners Goldman Sachs Abingworth Brookside Capital Ontario Teachers’ Pension Plan AllianceBernstein Eastern Capital Temasek D.E. Shaw Group Adage Capital Lightstone Ventures T. Rowe Price Pac-Link Janus Capital Group IBT Management Corporation & 1 more	N/A	-
Dec 2015*	N/A	$150m	Post IPO Equity
Sep 2017*	N/A	$349m	Post IPO Equity
Mar 2019*	Athyrium Capital Management HealthCare Royalty	$125m	Post IPO Debt
Aug 2019*	N/A	$259m	Post IPO Equity
May 2020*	Alexion Pharmaceuticals	$1.4b Valuation: $1.4b	Acquisition
Total Funding		€323m

Tech stackLearn more about the technologies and tools that this company uses.

Financials